Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
Clinics
;
66(12): 2141-2149, 2011. tab
Article
in English
| LILACS
| ID: lil-609014
ABSTRACT
Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Ibuprofen
/
Indomethacin
/
Cyclooxygenase Inhibitors
/
Ductus Arteriosus, Patent
/
Infant, Premature, Diseases
Limits:
Humans
/
Infant, Newborn
Language:
English
Journal:
Clinics
Journal subject:
Medicine
Year:
2011
Type:
Article
Affiliation country:
Italy
Institution/Affiliation country:
AOU University of Cagliari/IT
Similar
MEDLINE
...
LILACS
LIS